Prostate cancer is one of the leading
causes of death across the world. To diagnose prostate cancer,
physicians usually recommend a prostate-specific antigen test and
digital rectum test as preliminary investigations. If the results of
those tests are abnormal, physicians perform transrectal ultrasound,
biopsy, prostate cancer gene assay test, etc.. Furthermore, if
physicians want to find out whether the cancer has spread outside the
prostate, they can conduct a whole-body scan (using Technitium 99),
CT/CAT scan, PET-CT scan, MRI scan, etc.. Prostate-specific membrane
antigen (PSMA) is a cell surface antigen that is highly expressed in
prostate cancer. PSMA radionuclide labelled with positron emission
tomography (PET) imaging has been found to be superior to other
conventional imaging techniques for the diagnosis of prostate cancer.
Report Overview @ https://www.transparencymarketresearch.com/psma-pet-imaging-market.html
The global PSMA-PET imaging market is
primarily driven by an increase in the prevalence of prostate cancer in
the population across the globe. A consistent rise in the geriatric
population, sedentary lifestyle of people in developed countries, and a
high incidence of obesity at an early age are augmenting the prevalence
of prostate cancer globally. This propels demand for prostate cancer
diagnosis and therapies. In addition, launch of promising emerging
diagnostic methods, awareness about prostate cancer, higher rate of
diagnosis and treatment of prostate cancer, well-developed health care
infrastructure, and availability of health care reimbursement are likely
to fuel the global PSMA-PET imaging market in the coming years.
However, high cost of treatment of prostate cancer is estimated to
restrain the growth of the global PSMA-PET imaging market during the
forecast period. According to the Global Oncology Trend Report, global
prices of prostate cancer drugs and supportive care medicines increased
by 11.5% in 2015. Furthermore, a stringent regulatory scenario is
anticipated to present a barrier for the global PSMA-PET imaging market
during the forecast period.
There is a large undiagnosed patient pool
for prostate cancer globally, especially in developing countries where
health care facilities are not capable enough of taking care of the
diseased population. Governments are undertaking initiatives to address
this issue. Therefore, the number of reported patients is anticipated to
increase during the forecast period. A large undiagnosed patient
population is expected to provide a significant opportunity to the
global PSMA-PET imaging market during the forecast period.
In terms of type of prostrate cancer, the
global PSMA-PET imaging market can be segmented into acinar
adenocarcinoma, ductal adenocarcinoma, and others. Based on age group,
the global PSMA-PET imaging market can be classified into less than 55
years of age, aged between 55 and 75, and above 75 years of age. In
terms of end-user, the PSMA-PET imaging market can be categorized into
hospitals, diagnostic centers, and academic and research institutions.
Based on geography, the global PSMA-PET
imaging market can be segmented into North America, Europe, Asia
Pacific, Latin America, and Middle East & Africa. According to the
American Cancer Society, around 0.105% of the total male population in
the U.S. was documented as new cases of prostate cancer in 2017. The
Canadian Cancer Society estimated around 0.139% of the total male
population as new cases of prostate cancer in Canada in 2017. The
PSMA-PET imaging market in North America was expected to hold the
highest market share in 2017, owing to a high incidence of prostate
cancer in the region, availability of PSMA-PET imaging techniques, ,
high health care awareness, and technological advancements. The PSMA-PET
imaging market in Europe is anticipated to constitute a key market
share and expand at a robust pace during the forecast period. This is
due to a significantly high incidence of prostate cancer (0.113% of the
male population in Europe in 2017) and strong awareness of the
consequences of prostate cancer, availability of health care
reimbursement, and well-developed health care infrastructure in Western
Europe. The PSMA-PET imaging market in Asia Pacific is anticipated to
expand at a rapid CAGR during the forecast period, due to the developing
health care sector and increase in awareness about prostate cancer.
However, high cost of treatment, feeble medical infrastructure, low
awareness about prostate cancer, and low availability of the PSMA-PET
imaging method are likely to hamper the PSMA-PET imaging market in Latin
America and Middle East & Africa.
Key companies operating in the global
PSMA-PET imaging market are Fisher Scientific, Agilent Technologies,
Bio-Rad Laboratories, Inc., Abzena PLC.,Bayer Health, Blue Earth
Diagnostics, Inc, Endocyte, Aytu BioScience, Inc., Seattle Genetics,
Inc., Diagnostic BioSystems, and others.
No comments:
Post a Comment